Abstract
The field of cardiac pacing has been defined by constant development to provide efficacious, safe, and reliable therapy. Traditional pacing utilizes transvenous leads, which dwell in the venous system and place patients at risk for complications, including pneumothorax, bleeding, infection, vascular obstruction, and valvular compromise.
Leadless pacemakers have been developed to overcome many of the challenges of transvenous pacing while providing safe and effective pacing therapy for an increasing population of patients. The Medtronic Micra transcatheter pacing system was approved by the FDA in April of 2016 and the Abbott Aveir pacemaker was approved in April of 2022. Several additional leadless pacemakers are in various stages of development and testing. There exists limited guidance on the selection of the ideal candidate for leadless pacemakers.
Advantages of leadless pacemakers include decreased infection risk, overcoming limited vascular access, and avoidance of interaction with the tricuspid valve apparatus. Disadvantages of leadless pacemakers include right ventricular-only pacing, unclear lifecycle management, cost, perforation risk, and lack of integration with defibrillator systems. This review aims to provide an overview of the current state of the art of leadless pacemakers, currently approved systems, clinical trials and real-world evidence, considerations for patient selection, and future directions of this promising technology.
Graphical Abstract
[1]
Haydock P, Camm AJ. History and evolution of pacing and devices. Heart 2022; 108(10): 794-9.
[http://dx.doi.org/10.1136/heartjnl-2021-320149] [PMID: 35459730]
[http://dx.doi.org/10.1136/heartjnl-2021-320149] [PMID: 35459730]
[2]
Raatikainen MJP, Arnar DO, Merkely B, et al. A Decade of Information on the Use of Cardiac Implantable Electronic Devices and Interventional Electrophysiological Procedures in the European Society of Cardiology Countries: 2017 Report from the European Heart Rhythm Association. Europace 2017; 19(S2): ii1-ii90.
[http://dx.doi.org/10.1093/europace/eux258] [PMID: 28903470]
[http://dx.doi.org/10.1093/europace/eux258] [PMID: 28903470]
[3]
Udo EO, Zuithoff NPA, Van Hemel NM, et al. Incidence and predictors of short- and long-term complications in pacemaker therapy: The FOLLOWPACE study. Heart Rhythm 2012; 9(5): 728-35.
[http://dx.doi.org/10.1016/j.hrthm.2011.12.014] [PMID: 22182495]
[http://dx.doi.org/10.1016/j.hrthm.2011.12.014] [PMID: 22182495]
[4]
Kirkfeldt RE, Johansen JB, Nohr EA, Jorgensen OD, Nielsen JC. Complications after cardiac implantable electronic device implantations: An analysis of a complete, nationwide cohort in Denmark. Eur Heart J 2014; 35(18): 1186-94.
[http://dx.doi.org/10.1093/eurheartj/eht511] [PMID: 24347317]
[http://dx.doi.org/10.1093/eurheartj/eht511] [PMID: 24347317]
[5]
FDA approves first leadless pacemaker to treat heart rhythm disorders. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-leadless-pacemaker-treat-heart-rhythm-disorders
[6]
Reynolds DW, Ritter P. A Leadless intracardiac transcatheter pacing system. N Engl J Med 2016; 374(26): 2604-5.
[http://dx.doi.org/10.1056/NEJMc1604852] [PMID: 27355552]
[http://dx.doi.org/10.1056/NEJMc1604852] [PMID: 27355552]
[7]
Steinwender C, Khelae SK, Garweg C, et al. Atrioventricular synchronous pacing using a leadless ventricular pacemaker. JACC Clin Electrophysiol 2020; 6(1): 94-106.
[http://dx.doi.org/10.1016/j.jacep.2019.10.017] [PMID: 31709982]
[http://dx.doi.org/10.1016/j.jacep.2019.10.017] [PMID: 31709982]
[8]
Aveir Leadless Pacing System – Aveir Leadless Pacemaker, Model LSP112V (Right Ventricular); Aveir Delivery Catheter, Model LSCD111; and Aveir Link Module, Module LSL02 – P150035. Available from: https://www.fda.gov/medical-devices/recently-approved-devices/aveir-leadless-pacing-system-aveir-leadless-pacemaker-model-lsp112v-right-ventricular-aveir-delivery
[9]
Abbott. Instructions for Use. 2022. Available from: https://manuals.sjm.com/Search-Form?re=North-America&cc=US&ln=all&ct=professional&qry=Aveir&ipp=10
[10]
Roberts PR, Clementy N, Al Samadi F, et al. A leadless pacemaker in the real-world setting: The micra transcatheter pacing system post-approval registry. Heart Rhythm 2017; 14(9): 1375-9.
[http://dx.doi.org/10.1016/j.hrthm.2017.05.017] [PMID: 28502871]
[http://dx.doi.org/10.1016/j.hrthm.2017.05.017] [PMID: 28502871]
[11]
El-Chami MF, Al-Samadi F, Clementy N, et al. Updated performance of the micra transcatheter pacemaker in the real-world setting: A comparison to the investigational study and a transvenous historical control. Heart Rhythm 2018; 15(12): 1800-7.
[http://dx.doi.org/10.1016/j.hrthm.2018.08.005] [PMID: 30103071]
[http://dx.doi.org/10.1016/j.hrthm.2018.08.005] [PMID: 30103071]
[12]
Reddy VY, Exner DV, Cantillon DJ, Doshi R, Bunch TJ, Tomassoni GF. Percutaneous implantation of an entirely intracardiac leadless pacemaker. N Engl J Med 2015; 373(12): 1125-35.
[http://dx.doi.org/10.1056/NEJMoa1507192]
[http://dx.doi.org/10.1056/NEJMoa1507192]
[13]
Lakkireddy D, Knops R, Atwater B, Neuzil P, Ip J, Gonzalez E. A worldwide experience of the management of battery failures and chronic device retrieval of the Nanostim leadless pacemaker. Heart Rhythm 2017; 14(12): 1756-63.
[http://dx.doi.org/10.1016/j.hrthm.2017.07.004]
[http://dx.doi.org/10.1016/j.hrthm.2017.07.004]
[14]
Reddy VY, Exner DV, Doshi R, Tomassoni G, Jared Bunch T, Mark Estes N. Primary results on safety and efficacy from the leadless ii–phase 2 worldwide clinical trial. JACC Clin Electrophysiol 2021.
[http://dx.doi.org/10.1016/j.jacep.2021.11.002] [PMID: 34863657]
[http://dx.doi.org/10.1016/j.jacep.2021.11.002] [PMID: 34863657]
[15]
Johansen JB, Jørgensen OD, Møller M, Arnsbo P, Mortensen PT, Nielsen JC. Infection after pacemaker implantation: infection rates and risk factors associated with infection in a population-based cohort study of 46299 consecutive patients. Eur Heart J 2011; 32(8): 991-8.
[http://dx.doi.org/10.1093/eurheartj/ehq497] [PMID: 21252172]
[http://dx.doi.org/10.1093/eurheartj/ehq497] [PMID: 21252172]
[16]
El-Chami MF, Bonner M, Holbrook R, et al. Leadless pacemakers reduce risk of device-related infection: Review of the potential mechanisms. Heart Rhythm 2020; 17(8): 1393-7.
[http://dx.doi.org/10.1016/j.hrthm.2020.03.019] [PMID: 32247833]
[http://dx.doi.org/10.1016/j.hrthm.2020.03.019] [PMID: 32247833]
[17]
Koay A, Khelae S, Wei KK, Muhammad Z, Mohd Ali R, Omar R. Treating an infected transcatheter pacemaker system via percutaneous extraction. HeartRhythm Case Rep 2016; 2(4): 360-2.
[http://dx.doi.org/10.1016/j.hrcr.2016.04.006] [PMID: 28491710]
[http://dx.doi.org/10.1016/j.hrcr.2016.04.006] [PMID: 28491710]
[18]
Ellison K, Hesselson A, Ayoub K, Leung S, Gurley J. Retrieval of an infected leadless pacemaker. HeartRhythm Case Rep 2020; 6(11): 863-6.
[http://dx.doi.org/10.1016/j.hrcr.2020.08.022]
[http://dx.doi.org/10.1016/j.hrcr.2020.08.022]
[19]
Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 2021; 42(35): 3427-520.
[http://dx.doi.org/10.1093/eurheartj/ehab364] [PMID: 34455430]
[http://dx.doi.org/10.1093/eurheartj/ehab364] [PMID: 34455430]
[20]
Shehadeh M, Costello J, Brar V, Hadadi C. Successful micra leadless pacemaker implantation through an iliac vein stent. J Am Coll Cardiol 2020; 75(11): 2685.
[http://dx.doi.org/10.1016/S0735-1097(20)33312-X]
[http://dx.doi.org/10.1016/S0735-1097(20)33312-X]
[21]
Kolek MJ, Crossley GH, Ellis CR. Implantation of a MICRA leadless pacemaker via right internal jugular vein. JACC Clin Electrophysiol 2018; 4(3): 420-1.
[http://dx.doi.org/10.1016/j.jacep.2017.07.014] [PMID: 30089573]
[http://dx.doi.org/10.1016/j.jacep.2017.07.014] [PMID: 30089573]
[22]
Morani G, Bolzan B, Pepe A, Ribichini FL. Leadless pacemaker through tricuspid bioprosthetic valve: Early experience. J arrhythmia 2021; 37(2): 414-7.
[http://dx.doi.org/10.1002/joa3.12478] [PMID: 33850583]
[http://dx.doi.org/10.1002/joa3.12478] [PMID: 33850583]
[23]
Padala SK, Ellenbogen KA. Left bundle branch pacing is the best approach to physiological pacing. 2020; 1(1): 59-67.
[http://dx.doi.org/10.1016/j.hroo.2020.03.002]
[http://dx.doi.org/10.1016/j.hroo.2020.03.002]
[24]
Aveir DR. Aveir DR i2i Study. Patent NCT05252702 Available from: https://clinicaltrials.gov/ct2/show/NCT05252702
[25]
Okabe T, Hummel JD, Bank AJ, et al. Leadless left ventricular stimulation with WiSE-CRT System - Initial experience and results from phase I of SOLVE-CRT study (nonrandomized, roll-in phase). Heart Rhythm 2022; 19(1): 22-9.
[http://dx.doi.org/10.1016/j.hrthm.2021.06.1195] [PMID: 34332966]
[http://dx.doi.org/10.1016/j.hrthm.2021.06.1195] [PMID: 34332966]
[26]
Carabelli A, Jabeur M, Jacon P, Rinaldi CA, Leclercq C, Rovaris G. European experience with a first totally leadless cardiac resynchronization therapy pacemaker system. EP Eur 2021; 23(5): 740-7.
[27]
Bhatia NK, Kiani S, Merchant FM, et al. Life cycle management of Micra transcatheter pacing system: Data from a high‐volume center. J Cardiovasc Electrophysiol 2021; 32(2): 484-90.
[http://dx.doi.org/10.1111/jce.14825] [PMID: 33251698]
[http://dx.doi.org/10.1111/jce.14825] [PMID: 33251698]
[28]
Omdahl P, Eggen MD, Bonner MD, Iaizzo PA, Wika K. Right ventricular anatomy can accommodate multiple micra transcatheter pacemakers. Pacing Clin Electrophysiol 2016; 39(4): 393-7.
[http://dx.doi.org/10.1111/pace.12804]
[http://dx.doi.org/10.1111/pace.12804]
[29]
Dar T, Akella K, Murtaza G, et al. Comparison of the safety and efficacy of Nanostim and Micra transcatheter leadless pacemaker (LP) extractions: A multicenter experience. J Interv Card Electrophysiol 2020; 57(1): 133-40.
[30]
Satoh T, Fukui A, Katoh S, Matsui M. A leadless pacemaker which became encapsulated only two months after placement. Intern Med 2018; 57(20): 3053.
[http://dx.doi.org/10.2169/internalmedicine.1066-18]
[http://dx.doi.org/10.2169/internalmedicine.1066-18]
[31]
Kiani S, Merchant FM, El-Chami MF. Extraction of a 4-year-old leadless pacemaker with a tine-based fixation. HeartRhythm Case Rep 2019; 5(8): 424.
[http://dx.doi.org/10.1111/pace.12804] [PMID: 26710918]
[http://dx.doi.org/10.1111/pace.12804] [PMID: 26710918]
[32]
Afzal MR, Daoud EG, Cunnane R, et al. Techniques for successful early retrieval of the Micra transcatheter pacing system: A worldwide experience. Heart Rhythm 2018; 15(6): 841-6.
[33]
Campi T, Cruciani S, De Santis V, Maradei F, Feliziani M. Feasibility study of a wireless power transfer system applied to a leadless pacemaker. IEEE Wirel Power Transf Conf WPTC 2018.
[http://dx.doi.org/10.1109/WPT.2018.8639120]
[http://dx.doi.org/10.1109/WPT.2018.8639120]
[34]
The Micra TM transcatheter pacing system, a leadless pacemaker, in patients indicated for single-chamber ventricular pacemaker implantations. Health Technology Assessment 2018.
[35]
Hauser RG, Gornick CC, Abdelhadi RH, Tang CY, Casey SA, Sengupta JD. Major adverse clinical events associated with implantation of a leadless intracardiac pacemaker. Heart Rhythm 2021; 18(7): 1132-9.
[http://dx.doi.org/10.1016/j.hrthm.2021.03.015]
[http://dx.doi.org/10.1016/j.hrthm.2021.03.015]
[36]
Fong KY, Ng CJR, Wang Y, Yeo C, Tan VH. Subcutaneous versus transvenous implantable defibrillator therapy: A systematic review and meta-analysis of randomized trials and propensity score–matched studies. J Am Heart Assoc 2022; 11(11)e024756
[http://dx.doi.org/10.1161/JAHA.121.024756] [PMID: 35656975]
[http://dx.doi.org/10.1161/JAHA.121.024756] [PMID: 35656975]
[37]
Saeed M, Neason CG, Razavi M, et al. Programming antitachycardia pacing for primary prevention in patients with implantable cardioverter defibrillators: results from the PROVE trial. J Cardiovasc Electrophysiol 2010; 21(12): 1349-54.
[http://dx.doi.org/10.1111/j.1540-8167.2010.01825.x] [PMID: 20561107]
[http://dx.doi.org/10.1111/j.1540-8167.2010.01825.x] [PMID: 20561107]
[38]
Ng JB, Chua K, Teo WS. Simultaneous leadless pacemaker and subcutaneous implantable cardioverter-defibrillator implantation-When vascular options have run out. J Arrhythmia 2019; 35(1): 136.
[http://dx.doi.org/10.1002/joa3.12140]
[http://dx.doi.org/10.1002/joa3.12140]
[39]
Elliott MK, Sidhu BS, Mehta VS, Gould J, Martic D, Rinaldi CA. The importance of leadless pacemaker positioning in relation to subcutaneous implantable cardioverter-defibrillator sensing in completely leadless cardiac resynchronization and defibrillation systems. HeartRhythm Case Rep 2021; 7(9): 628-32.
[http://dx.doi.org/10.1016/j.hrcr.2021.06.006]
[http://dx.doi.org/10.1016/j.hrcr.2021.06.006]
[40]
Tjong FVY, Koop BE. The modular cardiac rhythm management system: The EMPOWER leadless pacemaker and the EMBLEM subcutaneous ICD. Herzschr Elektrophys 2018; 29(4): 355.
[http://dx.doi.org/10.1007/s00399-018-0602-y]
[http://dx.doi.org/10.1007/s00399-018-0602-y]
[41]
Piccini JP, Stromberg K, Jackson KP, et al. Patient selection, pacing indications, and subsequent outcomes with de novo leadless single-chamber VVI pacing. Europace 2019; 21(11): 1686-93.
[http://dx.doi.org/10.1093/europace/euz230] [PMID: 31681964]
[http://dx.doi.org/10.1093/europace/euz230] [PMID: 31681964]
[42]
El-Chami MF, Shinn T, Bansal S, et al. Leadless pacemaker implant with concomitant atrioventricular node ablation: Experience with the Micra transcatheter pacemaker. J Cardiovasc Electrophysiol 2021; 32(3): 832-41.
[http://dx.doi.org/10.1111/jce.14881] [PMID: 33428248]
[http://dx.doi.org/10.1111/jce.14881] [PMID: 33428248]
[43]
El-Chami MF, Johansen JB, Zaidi A, et al. Leadless pacemaker implant in patients with pre-existing infections: Results from the Micra postapproval registry. J Cardiovasc Electrophysiol 2019; 30(4): 569.
[http://dx.doi.org/10.1111/jce.13851] [PMID: 30661279]
[http://dx.doi.org/10.1111/jce.13851] [PMID: 30661279]
[44]
El-Chami MF, Bockstedt L, Longacre C, et al. Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up. Eur Heart J 2022; 43(12): 1207-15.
[http://dx.doi.org/10.1093/eurheartj/ehab767] [PMID: 34788416]
[http://dx.doi.org/10.1093/eurheartj/ehab767] [PMID: 34788416]
